4月份制造业采购经理指数有所回落 （四）预期指数保持扩张。生产经营活动预期指数为52.1%，继续位于扩张区间。部分行业企业对近期 发展信心较强，其中食品及酒饮料精制茶、汽车、铁路船舶航空航天设备等行业生产经营活动预期指数 均位于58.0%及以上较高景气区间。 非制造业商务活动指数继续保持扩张 ——国家统计局服务业调查中心高级统计师赵庆河解读2025年4月中国采购经理指数 2025年4月30日国家统计局服务业调查中心和中国物流与采购联合会发布了中国采购经理指数。对此， 国家统计局服务业调查中心高级统计师赵庆河进行了解读。 4月份，制造业采购经理指数为49.0%，比上月下降1.5个百分点；非制造业商务活动指数和综合PMI产 出指数分别为50.4%和50.2%，继续保持在扩张区间。 一、制造业采购经理指数有所回落 4月份，受前期制造业较快增长形成较高基数叠加外部环境急剧变化等因素影响，制造业PMI为49.0%， 回落至临界点以下。 （一）产需两端均有放缓。生产指数和新订单指数分别为49.8%和49.2%，比上月下降2.8和2.6个百分 点，制造业生产和市场需求均有所回落。从行业看，农副食品加工、食品及酒饮料精制茶、 ...

Group 1 - The company operates primarily in the pharmaceutical and health industry, focusing on pharmaceutical manufacturing, retail, research, and investment [3] - The company has approximately 128 drug production licenses, including 55 products listed in the national medical insurance directory [3] - The company has one new drug under research and five unique products or dosage forms nationwide [3] Group 2 - The company received a non-standard audit opinion from Beijing Dehao International Accounting Firm, indicating an inability to express an opinion on the financial report [2] - The company has not distributed cash dividends or bonus shares during the reporting period [2] - The company has initiated bankruptcy reorganization to address historical debt pressures and improve operational sustainability [6][7] Group 3 - The company is at risk of delisting due to its stock price being below 1 yuan for twenty consecutive trading days [8] - The Shenzhen Stock Exchange has issued a notice indicating the intention to terminate the company's stock listing [8]

联合研究丨组合推荐 [Table_Title] 大消费行业 2025 年 5 月金股推荐 %% %% %% %% research.95579.com 1 丨证券研究报告丨 报告要点 [Table_Summary] 长江大消费九大优势行业（农业、零售、社服、汽车、纺服、轻工、食品、家电、医药）2025 年 5 月重点推荐金股。 分析师及联系人 [Table_Author] 陈佳 李锦 赵刚 SAC：S0490513080003 SAC：S0490514080004 SAC：S0490517020001 SFC：BQT624 SFC：BUV258 SFC：BUX176 高伊楠 于旭辉 蔡方羿 SAC：S0490517060001 SAC：S0490518020002 SAC：S0490516060001 SFC：BUW101 SFC：BUU942 SFC：BUV463 董思远 陈亮 彭英骐 SAC：S0490517070016 SAC：S0490517070017 SAC：S0490524030005 SFC：BQK487 SFC：BUW408 SFC：BUZ392 请阅读最后评级说明和重要声明 2 / 11 ...

Investment Rating - The investment rating for the company is "Outperform" (maintained) [1] Core Insights - The company reported a strong recovery in performance with a 10.10% year-on-year increase in revenue for Q1 2025, reaching 1.541 billion yuan, driven by rapid growth in emerging businesses [4][7] - The net profit attributable to shareholders increased by 15.83% year-on-year to 327 million yuan, with a notable 20.14% growth in non-recurring net profit, indicating effective cost management and improved gross margins in emerging businesses [4][7] - Emerging businesses, including peptides and oligonucleotides, showed impressive growth with revenue increasing over 80% and gross margins improving to 33.05% [7] Financial Data and Profit Forecast - Total revenue forecast for 2025 is 6.468 billion yuan, with a projected year-on-year growth rate of 11.4% [6] - The net profit forecast for 2025 is 1.071 billion yuan, reflecting a 12.9% increase compared to the previous year [6] - The company expects to maintain a stable gross margin of around 43.2% in 2025, with a gradual increase in return on equity (ROE) from 6.0% in 2025 to 6.9% in 2027 [6][7]

文 | 银行螺丝钉 （转载请注明出处） 今天大盘微涨微跌，波动不大，截止到收盘，还在5.1星。 大盘股波动不大，小盘股上涨。 医疗、科技等上涨。 医药行业几个龙头公司发布财报，盈利增长逐渐恢复，带动今天医药医疗比较强势。 港股微涨，港股科技股领涨。 港股科技股在4月初大跌后重回低估。 这两周上涨比较多，目前还在低估，不过距离正常估值也比较接近了。 1. 最近市场进入了震荡期，连着两周，大盘上下波动都比较小。 马上就是五一假期了。 本周二周三还是正常交易。 本周二发车也继续。 过了周三15点，就进入假期，基金也暂停交易；下周二恢复正常。 假期里就不用买卖基金了，假期里申购赎回也是等假期后才成交。 2. [大吉大利，今天吃基] 第362期的螺丝钉定投实盘来啦。 时间：2025年4月29日 方案：定投买入 品种： 指数增强投顾组合：11579元 主动优选投顾组合： 12878元 其实在整个历史上，大约只有7%的时间是市场大幅上涨的阶段，其他时间是震荡和下跌行情。 但也就是这7%的时间，带来了市场大多数的回报。 点击下图，即可立即跟投买入： 点击下图，即可立即跟投买入： 定投 金额采用的是 「定期不定额」的策略，估值 ...

强强联合：科技赋能大健康产业 温江现代服务业战区作为现代服务产业示范区，长期致力于促进服务业数字化转型与跨界融合。京润未 来此次合作，旨在整合政策、技术、市场资源，加速大健康产业与数字经济的深度结合，将为项目提供 完善的产业配套和试验场景，形成"科技+医疗+医药+健康"的创新模式。 京润未来董事长张兴民表示："此次合作是京润未来智能化升级的关键一步。此前，京润未来先后构建 了润心智慧云医大药房、御君方互联网医院、芳华未来医疗健康服务平台等业务板块，逐步形成以医药 批发、医药电商零售、互联网医疗、健康管理、中医教育等多元化健康产业发展布局。本次合作，京润 未来将依托温江现代服务业战区的资源支持和区位优势，以数字化手段持续深化医疗、医药、健康管理 等与AI、5G、区块链技术等融合，让更多人享受便捷、精准、普惠的健康服务，积极响应国家战略， 为"健康中国"、"智慧养老"不断贡献力量。" 三大核心板块：构建互联网+医疗大健康数字化生态 1.御君方互联网医院：让每一个国人都有家庭医生 2025年4月28日，北京京润未来科技有限公司与温江现代服务业战区签署了《京润未来科技西部总部项 目投资协议》，双方将共同推动大健康产业 ...

777只股公布截至4月20日最新股东户数，相比上期股东户数下降的有373只，降幅居前的是哈三联、山 水比德、丰乐种业等。 投资者除了在定期报告中获得股东信息数据外，还可以在交易所互动平台上通过提问方式了解部分公司 更及时（每月10日、20日、月末）的股东户数信息。以往3期分别有874家、4895家、745家公司在互动 平台透露了股东户数，截至发稿，共有777家公司公布了截至4月20日股东户数。 上期筹码集中股回测：31%跑赢沪指 证券时报·数据宝对上一期(4月10日)筹码集中股监测显示，这些股4月1日以来平均下跌3.93%，走势弱于 同期沪指表现（下跌1.47%），其中，31%的筹码集中股相对大盘获超额收益。 上期股东户数降逾一成个股中，康弘药业涨幅最高，4月1日以来累计上涨11.94%，涨幅居前的还有宏 盛股份、北方华创等。 10股最新股东户数降逾一成 证券时报·数据宝统计显示，共有777只个股公布了4月20日股东户数，与上期（4月10日）相比，股东户 数下降的有373只。其中股东户数降幅超一成的有10只。 股东户数降幅最多的是哈三联，截至4月20日最新股东户数为41802户，较4月10日下降26.12%， ...

证券代码：600568 证券简称：ST 中珠 公告编号：2025-022 号 中珠医疗控股股份有限公司 2025 年第一季度主要经营数据公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司行业信息披露指引第一号——房地产》《上市公司行业信息披露 指引第六号——医药制造》及上海证券交易所《关于做好主板上市公司 2025 年第一季 度报告披露工作的重要提醒》的要求，中珠医疗控股股份有限公司（以下简称"中珠 医疗"或"公司"）现将 2025 年第一季度主要经营数据披露如下： 一、主营业务分析 | 行 业 | 营业收入 | 营业成本 | 毛利率 | 营业收入比 | 营业成本比 | | --- | --- | --- | --- | --- | --- | | | （2025 年 1-3 月） | （2025 年 1-3 月） | | 上年增减（%） | 上年增减（%） | | 医疗器械 | 2,225,707.17 | 1,631,908.30 | 26.68 | -59.06 | -55.10 | | 医疗 ...

Investment Rating - The report maintains a "Recommended" investment rating for Shanghai Pharmaceuticals (601607.SH) [1][7] Core Views - The company reported a revenue of 70.763 billion yuan in Q1 2025, a year-on-year increase of 0.87%, while the net profit attributable to shareholders decreased by 13.56% to 1.333 billion yuan [3][4] - The company has a strong cash position with 36.167 billion yuan in cash as of Q1 2025, representing a year-on-year growth of 20.40%, which supports ongoing mergers and acquisitions [7][8] - The acquisition of a 10% stake in Shanghai Hutchison Pharmaceuticals, increasing total ownership to 60%, is expected to enhance the company's traditional Chinese medicine business [7][8] - Future performance is projected to grow, with net profits expected to reach 5.419 billion yuan in 2025, 6.169 billion yuan in 2026, and 6.612 billion yuan in 2027 [7][8] Financial Summary - Revenue projections for 2025 are set at 297.932 billion yuan, with a year-on-year growth of 8.2% [6][8] - The net profit for 2025 is estimated at 5.419 billion yuan, reflecting a growth of 19.0% compared to 2024 [6][8] - The gross margin is expected to stabilize around 10.9% in 2025, while the net margin is projected to be 1.8% [6][8] - The company’s return on equity (ROE) is forecasted to improve to 7.1% in 2025 [6][8] - The price-to-earnings (P/E) ratio is projected to decrease to 12.4 in 2025, indicating a potentially attractive valuation [6][8]

Core Insights - The company is facing a deep crisis during its transformation period, with financial results showing a decline in revenue and net profit, indicating a struggle with dual weak business segments and cash flow issues [1] - The cosmetics segment, which accounts for over 60% of revenue, is experiencing significant challenges, with reliance on a single product leading to an imbalanced brand portfolio [2] - The strategic transition towards a dual business model of pharmaceuticals and cosmetics is hindered by slow innovation and cash flow deterioration, raising concerns about the company's market competitiveness [3] - To overcome its challenges, the company needs to strengthen its core competencies, innovate in product development, and optimize capital efficiency [4] Financial Performance - Revenue for Q1 2025 was 876 million yuan, a year-on-year decline of 1.63% [1] - Net profit attributable to shareholders was 51 million yuan, down 14.10% year-on-year [1] Cosmetics Business Challenges - The cosmetics segment's over-reliance on a single bestselling product has led to a structural imbalance, with other brands experiencing significant revenue declines [2] - High sales expenses have not translated into sustainable growth, resulting in increased accounts receivable and inventory issues [2] - Online sales growth is lagging behind industry averages, while offline channels are suffering from reduced foot traffic [2] Strategic Transition Issues - The pharmaceutical segment's revenue has slightly decreased, and new product trials have shown limited success [3] - The company's claims of integrating AI and data into its operations remain largely conceptual, with significant challenges in product line management and innovation [3] - Cash flow issues are exacerbated by rising accounts receivable and shortened accounts payable cycles, indicating weakened bargaining power [3] Recommendations for Improvement - The company must solidify its technological barriers in the cosmetics sector and innovate active ingredients to reduce reliance on bestsellers [4] - Accelerating the research and development of pharmaceutical products and genuinely integrating AI into product development processes is crucial [4] - Improving capital efficiency and focusing on strategic initiatives rather than blind expansion is necessary to regain market share [4]